Intermediate Vision in a Driving Simulator Environment: Comparison of the J&J EYHANCE With a Conventional Monofoc. IOL (JJ-EYHANCE)

March 28, 2020 updated by: Aalen University

Intermediate Vision in a Driving Simulator Environment: Comparison of the New J&J EYHANCE IOL With a Conventional Monofocal IOL

To compare (low contrast) visual acuity (VA) and contrast sensitivity (CS) - both at intermediate distances under nighttime driving conditions in a driving simulator between patients with bilateral EYHANCE IOLs OR bilateral conventional monofocal IOLs. Visual function testing in the driving simulator will be assessed without AND with (static) glare.

Additionally: Assessment of individual response times, scanpath characteristics, evaluation of test retest reliability and self-evaluation of (intermediate) vision and visual impairment related to glare.

Study Overview

Detailed Description

To compare (low contrast) visual acuity (VA) and contrast sensitivity (CS) - both at intermediate distances under nighttime driving conditions in a driving simulator between patients with bilateral EYHANCE IOLs OR bilateral conventional monofocal IOLs. Visual function testing in the driving simulator will be assessed without AND with (static) glare.

Additionally: Assessment of individual response times, scanpath characteristics, evaluation of test retest reliability and self-evaluation of (intermediate) vision and visual impairment related to glare.

Simulator

Patients are instructed to drive with a constant speed of 40 km/h on a virtual parcours (straight lane). For testing of either (low contrast) visual acuity or contrast sensitivity, 8-position LANDOLT C's are presented at three locations (within the simulator car, AUDI A4, Ingolstadt/FRG):

(i) At the center of the instrument panel (distance 0.xx m) (ii) At the center of the navigation monitor (y.yy m) (iii) At the center of the rear monitor (z.zz m) A high resolution acoustic attention guidance for immediate gaze direction of the patients towards the three above-mentioned visual stimulus locations (i-iii) is mandatory.

Patients responses are recorded and response times can be extracted from the recordings.

Clinical ophthalmological-optical examinations

  • Medical/ophthalmological history
  • (Uncorrected and Best-corrected) visual acuity (RE,LE,BE) with remote and intermediate (66cm) 8 position LANDOLT C's.
  • LANG I stereotest (near distance)
  • Ocular alignment & ocular motility
  • Efferent & afferent pupillomotor status
  • Mesopic contrast sensitivity without/with glare (Optovist, VISTEC Inc./Olching/FRG)
  • Intraocular straylight perception (Q-Quant, OCULUS Inc, Wetzlar/FRG)
  • Slit lamp (anterior segment)
  • Ophthalmoscope (central fundus and fixation)

    • Primary objectives: log visual acuity (logVA) at preset low contrast level of 1:2.7 (logCS = 0.2) AND log contrast sensitivity (logCS) at a preset visual acuity level of 0.1 = 2/20)
    • Secondary objectives: test retest reliability (as operationalized by LOA = limits of agreement) AND response time (i.e. time interval between onset of stimulus presentation and final response) AND scanpath characteristics (fixation duration, fixation stability, annotation to regions of interest; saccade amplitude) self-evaluation (questionnaire, using visual analogue scales = VAS)

SHAPIRO WILK test (statistical testing for proving/disproving normal distribution) Descriptive statistics (either MEAN, standard deviation, in case of normally distributed data - else, MEDIAN, inter-quartile range (IQR).

Assessment of test/retest reliability: BLAND ALTMAN plots, limits of agreement (LOA) Between-group comparison: t-test (unpaired samples), in case of normally distributed data - else, WILCOXON signed-rank test

Study Type

Observational

Enrollment (Actual)

11

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Baden-Württemberg
      • Aalen, Baden-Württemberg, Germany, 73430
        • University of Applied Sciences, Study Course Ophthalmic Optics

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Subjects of male or femal gender above the age of 18 years at least two months post surgery after bilateral uneventful IOL surgery (bilateral implantation of either EYHANCE IOL OR monofocal IOL)

Description

Inclusion Criteria:

  • Informed consent
  • S.p. (at least two months post surgery) bilateral uneventful IOL surgery (bilateral implantation of either EYHANCE IOL OR monofocal IOL)
  • Ophthalmological history normal, except cataract and uneventful IOL surgery
  • Distant visual high-contrast acuity > 20/25 in either eye
  • Normal stereopsis (all figures of the LANG I random dot stereo test correctly recognized)

Exclusion Criteria:

  • Age below 18 years
  • Chronic eye disease (except cataract)
  • History of ocular surgery (except complication-free IOL surgery)
  • Visual pathway lesions
  • Strabismus

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Intraocular lens type I
Tecnis EYHANCE IOL (Johnson & Johnson, New Brunswick/USA)
This is NOT an interventional study; the intervention (surgical procedure) has been performed PRIOR to the inclusion in this study
Other Names:
  • Tecnis EYHANCE IOL (Johnson & Johnson, New Brunswick/USA)
  • Clareon IOL (Alcon Pharma. Freiburg/FRG)
Intraocular lens type II
Clareon IOL (Alcon Pharma. Freiburg/FRG)
This is NOT an interventional study; the intervention (surgical procedure) has been performed PRIOR to the inclusion in this study
Other Names:
  • Tecnis EYHANCE IOL (Johnson & Johnson, New Brunswick/USA)
  • Clareon IOL (Alcon Pharma. Freiburg/FRG)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
logVA
Time Frame: at least two months after uneventful intraocular lens implantation
logarithm of visual acuity at preset low contrast level of 1:2.7 (logCS = 0.2)
at least two months after uneventful intraocular lens implantation
logCS
Time Frame: at least two months after uneventful intraocular lens implantation
logarithm of contrast sensitivity at a preset visual acuity level of 0.1 (= 2/20)
at least two months after uneventful intraocular lens implantation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reproducibilities of logVA
Time Frame: at least two months after uneventful intraocular lens implantation
as operationalized by LOA (limits of agreement)
at least two months after uneventful intraocular lens implantation
Resonse times of logCS
Time Frame: at least two months after uneventful intraocular lens implantation
time interval between onset of stimulus presentation amd final response
at least two months after uneventful intraocular lens implantation
Scanpath characteristics (I)
Time Frame: at least two months after uneventful intraocular lens implantation
fixation duration
at least two months after uneventful intraocular lens implantation
Scanpath characteristics (II)
Time Frame: at least two months after uneventful intraocular lens implantation
fixation stability
at least two months after uneventful intraocular lens implantation
Scanpath characteristics (III)
Time Frame: at least two months after uneventful intraocular lens implantation
annotation to regions of interest (ROIs)
at least two months after uneventful intraocular lens implantation
Scanpath characteristics (IV)
Time Frame: at least two months after uneventful intraocular lens implantation
saccade amplitude
at least two months after uneventful intraocular lens implantation
Self-evaluation (questionnaire) (i) distant vision with best distant correction
Time Frame: at least two months after uneventful intraocular lens implantation
Distant vision (self-eval., vis. analogue scales: 0 = unsatisfactory ... 10 = optimal)
at least two months after uneventful intraocular lens implantation
Self-evaluation (questionnaire) (i) intermediate vision with best distant correction
Time Frame: at least two months after uneventful intraocular lens implantation
Intermed. vision (self-eval., vis. analog. scales: 0 = unsatisfactory ... 10 = optimal)
at least two months after uneventful intraocular lens implantation
Self-evaluation (questionnaire) (i) mesopic vision with best distant correction
Time Frame: at least two months after uneventful intraocular lens implantation
Mesopic vision (self-eval., vis. analog. scales: 0 = unsatisfactory ... 10 = optimal)
at least two months after uneventful intraocular lens implantation
Self-evaluation (questionnaire) (i) glare sensitivity with best distant correction
Time Frame: at least two months after uneventful intraocular lens implantation
Glare sensitivity (self-eval., vis. analog. scales: 0 = unsatisfactory ... 10 = optimal)
at least two months after uneventful intraocular lens implantation
Self-evaluation (questionnaire) (i) General post-op vision with best distant corr.
Time Frame: at least two months after uneventful intraocular lens implantation
Post-op vision (self-eval., vis. analog. scales: 0 = unsatisfactory ... 10 = optimal)
at least two months after uneventful intraocular lens implantation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 7, 2020

Primary Completion (Actual)

March 15, 2020

Study Completion (Actual)

March 15, 2020

Study Registration Dates

First Submitted

August 8, 2019

First Submitted That Met QC Criteria

August 14, 2019

First Posted (Actual)

August 16, 2019

Study Record Updates

Last Update Posted (Actual)

March 31, 2020

Last Update Submitted That Met QC Criteria

March 28, 2020

Last Verified

August 1, 2019

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lenses, Intraocular

Clinical Trials on Posterior chamber intraocular lens (IOL)

3
Subscribe